January 8, 2018 / 12:14 PM / a year ago

BRIEF-Kamada Announces Data From Phase 2 Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment For Prevention Of Lung Transplant Rejection

Jan 8 (Reuters) - Kamada Ltd:

* KAMADA ANNOUNCES INTERIM RESULTS FROM PHASE 2 CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION

* KAMADA LTD - TOP-LINE RESULTS FROM PHASE 2 TRIAL OF ALPHA-1 ANTITRYPSIN ANTICIPATED IN H2 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below